- \overline{a} 1 Harnessing methods, data analysis, and near-real-time wastewater monitoring for enhanced public
2 health response using high throughput sequencing.
-
- 3 Padmini Ramachandran^{1*}, Tunc Kayikcioglu^{1,2}, Tamara Walsky¹, Kathryn Judy¹, Jasmine Amirzadegan¹,
- 3 Padmini Ramachandran* , Tunc Kayikcioglu*'*, Tamara Walsky*, Kathryn Judy*, Jasmine Amirzadegan* ,
4 Candace Hope Bias¹, Bereket Tesfaldet¹, Maria Balkey, Dietrich EppSchmidt^{1,2}, Hugh Rand¹, James
- 4 Candace Hope Bias*, Bereket Tesfaldet*, Maria Balkey, Dietrich EppSchmidt*/*, Hugh Rand*, James
5 Pettengill¹, Sandra Tallent¹, Eric Brown¹, Tina Pfefer¹, Ruth Timme¹, Amanda Windsor¹ , Christophe 5 Pettengill", Sandra Tallent", Eric Brown", Tina Pfefer", Ruth Timme", Amanda Windsor" , Christopher
6 Grim¹, and Maria Hoffmann¹
- Pettengill⁺, Sandra Tallent⁺
Grim¹, and Maria Hoffman 6 Grimf, and Maria Hoffmannf
7 1 ContacfacFaceLGefa
- 7 1. Center for Food Safety and Applied Nutrition, Food and Drug Administration, Office of
8 Regulatory Science, Division of Microbiology, HFS-712, 5001 Campus Drive, College Park, MD
- 8 Regulatory Science, Division of Microbiology, HFS-712, 5001 Campus Drive, College Park, MD
9 20740, USA.
-
- 9 20740, USA.
10 2. Joint Institute for Food Safety and Applied Nutrition, University of Maryland, 5825, University
- 11 2. Besearch Ct, Suite 1400, College Park, MD, USA. 11 Research Ct, Suite 1400, College Park, MD, USA.
12
- 12
13
- 13 Address correspondence to:
14 Padmini Ramachandran
-
- 15 5001, Campus Drive, 4E-019,
- 16 College Park, MD-20740.
- 17 Ph no: 3017960610
- 18 Email: Padmini.ramachandran@fda.hhs.gov 19 Email: <u>Padmini.ramachandran ann 1984</u>
19
- 19
20
-
- 21
- 22
-
- 22
-
- 24

$\overline{1}$ 25 **Abstract**
26 Metatric

26 Wastewater-based analysis has emerged as a pivotal method for monitoring SARS-CoV-2 (SC2).
27 Leveraging high-throughput sequencing on wastewater samples facilitates a comprehensive, population-28 Level assessment of circulating and emerging SC2 variants within a community. This study meticulously 29 evaluates the detection performance, variant calling accuracy, and the time taken from sample 30 collection to public data release for wastewater SC2 monitoring. We employed two different SC2 target 31 enrichment panels on Illumina MiSeq and Oxford Nanopore Technologies (ONT) GridION sequencing 32 platforms for a robust analysis. Daily collection of routine raw grab and composite samples took place at 33 a wastewater treatment plant (WWTP) site in Maryland, USA (MD) from mid-January 2022 to the end of 34 June 2022. Total Nucleic Acid (TNA) was extracted from samples and target enrichment was executed 35 using QIAseq DIRECT and NEBNext VarSkip Short amplicon kits, with subsequent sequencing on MiSeq 36 vor ONT GridION platforms, respectively. Obtained sequences was analyzed using our custom CFSAN 37 Wastewater Analysis Pipeline (C-WAP). Raw sequence data and detailed metadata were submitted to 38 NCBI (BioProject PRJNA757291) as it became available. Our wastewater data successfully detected the 39 onset of new variants BA.2, BA.2.12, BA.4.6, and BA.5 to the observed population. Notably, Omicron 40 sub-variants were identified approximately a week ahead of publicly available clinical data at the MD 41 ZIP-code level. Variation in quality metrics paralleled the rise and fall of BA waves, underscoring the 42 impact of viral load on sequencing quality. Regular updates of estimated variant proportions were made 43 available on the FDA-CFSAN "Wastewater Surveillance for SARS-CoV-2 Variants" website. In contrast to 44 the median 28-day turnaround for our samples, the lead time from sample collection to public release of 45 the median 28-dag median 28-dagger median 28-dagger median in the median collection for specific 46 exercise. Our processing, sequencing, and analysis methods empowered the swift and accurate 47 detection of SC2 trends and circulating variants within a community, offering insights for public health 17 detection of SC2 trends and circulating variants within a community, offering insights for public health.
48 decision-making. 48 decision-making.

 $\overline{2}$

$\overline{}$

49 Keywords
50 Wastewater, surveillance, SARS-CoV-2, sequencing

50 Wastewater, surveillance, SARS-CoV-2, sequencing

- 51 Abbreviations
52 SARS-CoV-2 (SC2), Wastewater treatment plant (WWTP), Total Nucleic Acid (TNA), CFSAN Wastewater
- 52 SARS-COV-2 (SC2), Wasterwater treatment plant (WWW, Total Nucleic Acid, TSAN Wastewater
53 Analysis Pipeline (C-WAP), 53 Analysis Pipeline (C-WAP).
-
-
- 54
- 55
-
- 57
-
- 58
-
- 58
- 59
-
- 61
- 62
-
- 62
-
- 63
- 65
- 65
-
- 67

$\overline{}$

89 abundance in mixed population samples such as wastewater. While deep sequencing without prior

90 amplification may be efficient for viruses that reside in high quantity in plasma, in a mixed population of 90 amplification may be efficient for viruses that reside in high quantity in plasma, in a mixed population of

 $\overline{4}$

 \overline{a} 91 variants and a complex environmental matrix like wastewater, sequencing without amplification is
92 impractical (8). For wastewater-based viral detection, implementation of a multiplexed target 93 enrichment panel is necessary. However, there are challenges in the analysis of sequencing reads from 94 target enrichment panels for accurate identification of multiple variants in a single sample. Here we use 95 an analysis pipeline, the CFSAN Wastewater Analysis Pipeline (C-WAP, https://github.com/CFSAN-96 Biostatistics/C-WAP), for identification and abundance estimation of circulating variants. As SC2 evolves 97 and new variants arise, continued monitoring for emerging variants will be an important component of 98 public health efforts (9). As the virus evolves, enrichment kits, databases of variants, and detection 99 methods will also need to evolve and be re-evaluated to ensure the best possible methods are in use.

100 The application of high-throughput sequencing for the rapid identification and surveillance of 101 pathogens has recently become common place in public health systems (10-12). The SC2 pandemic has 102 helped bring WBE to the forefront of community-scale pathogen surveillance (7, 13). Here, we describe 103 how monitoring wastewater from urban areas can be used to detect the arrival of emerging SC2 variants 104 of SC2 in a chosen sewer shed. This study adapted two different target enrichment panels, initially 105 designed for clinical samples, for application in wastewater samples. Additionally, both protocols were 106 optimized and published to protocols io (14). The study established critical quality control checkpoints 107 within the laboratory workflow and on the analysis of sequence data derived from a mixed population of 108 wastewater samples. The evaluation encompassed the detection performance and variant calling 109 accuracy using two different SC2 target enrichment panels, covering $99.16 + / - 0.58\%$ of the SC2 genome 110 conducted on both Illumina MiSeg and Oxford Nanopore Technologies (ONT) GridION sequencing 111 platforms. A crucial aspect explored was the turn-around-time from sample collection to public data 112 release, recognizing its significant public health impact. The findings demonstrated the effectiveness of 113 high-throughput sequencing of SC2 genomes from wastewater. The incorporation of precision analysis 113 high-throughput sequencing of SC2 genomes from wastewater. The incorporation of precision analysis
.

 \mathbf{t} 115 tools, such as C-WAP, facilitated the early detection of emerging variants of concentration and the early
115 samples.

134 Composites were collected as 1L grabs from Feb23rd 2022 till June 28th, 2022. Composites were 135 aliquoted from the auto sampler (auto sampler has a collection interval of 30 mins for 24hrs) as two-1L 136 grabs in Nalgene bottles and stored at 4°C until use. Each biological replicate per week after pooling was 136 grabs in Nalgene bottles and stored at 4°C until use. Each biological replicate per week after pooling was

- \overline{a} \mathbf{t} 137 then split into three 40mL technical replicates, resulting in six samples per week (Supplementary table 1,
138 Schematic Fig 1). The complete workflow for this study is described in detail in Fig1.
-

139 Total nucleic acid extraction and SARS-CoV-2 RT-qPCR detection

- 140 Sample concentration and total nucleic acid extraction was performed on the pooled
- 141 wastewater using Maxwell RSC Enviro TNA Kit (Promega, Madison, WI USA) following manufacturer's
- 142 recommendations. The extracted total nucleic acid was stored at -20 C for short term (a week) to
- 143 process for the cDNA generation and RT-qPCR. After the necessary amount was aliquoted, the TNA was
- 144 stored at -80 C for long term storage. The detailed protocol has been published in
- 144 stored at -80 C for long term storage. The detailed protocol has been published in detailed in the detailed in dx doi.org/10.17504/protocols.io.rm7vzy52xlx1/v1. 145 dx.doi.org/10.17504/protocols.io.rm7vzy52xlx1/v1.
- The quantification of SARS-CoV-2 in wastewater was performed utilizing the Promega GoTaq®
147 Finviro Wastewater SARS-CoV-2 System, which targets the N1 gene (Promega, Madison, WI USA)
-
- 148 following manufacturer's recommendations. This includes guidance for converting RT-qPCR output into
- 149 calculated viral genome copies per liter.
- 150 DNA digestion and cDNA synthesis 150 DNA digestion and cDNA synthesis
- 151 Genomic DNA was digested with ezDNase (Invitrogen, Waltham, MA USA) with protocol
152 modifications. Reaction cocktails consisted of 10uL template TNA, 2uL nuclease free water, 1uL
-
- 153 ezDNase[™] buffer, and 1 µL ezDNase[™] enzyme. Reactions were then digested at 37°C for 5 minutes.
- 154 Digestion was stopped by addition of 1µL 10mM DTT and a 5-minute incubation at 55°C. Reactions were
- 155 chilled on ice for at least 1 minute before proceeding to cDNA synthesis.
- 156 cDNA was synthesized from the purified RNA with the Superscript IV Reverse Transcriptase
- 157 (Invitrogen, Waltham, MA, USA) with modifications to the manufacturer protocol. Primer annealing was
- 158 carried out with 1µL 50µM random hexamers, 1uL 10mM dNTP mix, 1µL DEPC-treated water, and 10µL 158 carried out with 1µL 50µM random hexamers, 1uL 10mM dntp mix, 1uL 10mM dntp mix, 1uL DePC-treated water, a
The contract water, 1uL 10mM dntp mix, 100mM d

 \mathbf{t} 159 template RNA. Reactions were incubated at 65°C for 5 minutes, then incubated on ice for at least 1
160 minute. The Reverse Transcriptase reaction mix was prepared with 4µL 5x SSIV Buffer, 1 µL 100mM DTT, 161 1µL RNaseOUT[™] Recombinant RNase Inhibitor, and 1uL SuperScript IV Reverse Transcriptase (200U/µL) 162 and then added to the chilled primer-annealed RNA. Reactions were then incubated at 23°C for 10 163 minutes, 50°C for 30 minutes, then 80°C for 10 min. cDNA was stored at -20°C until use.

$\frac{1}{2}$ minutes, $\frac{1}{2}$ for $\frac{1}{2}$ for $\frac{1}{2}$ for $\frac{1}{2}$ minutes, then $\frac{1}{2}$ was stored at $\frac{1}{2}$ was st

Selection of enrichment panels for this study.
165 October through December 2021, we evaluated some commercially available SC2 enrichment 166 panels. Enrichment panels for assessment were chosen based on multiple criteria. Our main objective 167 was to ensure even coverage across the genome; therefore, we chose kits with tiled amplicon across the 168 entire SC2 genome and simple library preparation of these amplicons to achieve rapid, simple, and cost-169 effective sequencing. Read lengths of the amplicon to adapt to both short read sequencing chemistry 170 and long read sequencing chemistry were also considered. The commercial enrichment panels that were 171 assessed initially included Midnight FREED primers (1200 bp long amplicons with Oxford Nanopore 172 library and sequencing) (15), SWIFT SNAP additional genome coverage panel (150 bp long amplicons 173 with Illumina MiSeq sequencing) (16), NEBNext VarSkip Short primers (560 bp long, with possibility of 174 sequencing in both Illumina and ONT platform) (17), and QIAseq DIRECT enrichment panel (250 bp 175 amplicons with Illumina MiSeg sequencing). Based on the ease of generating the amplicons, ease of 176 library preparation and adaptability of the amplicons with different sequencing platforms we chose two 177 enrichment panels for this study that are discussed in detail in this manuscript, QIAseq DIRECT and 178 NEBNext VarSkip Short (NEB VSS). The QIAseq DIRECT panel has 222 primer pairs with average amplicon 179 Iength of 250 bp while the NEB VSS panel has 74 primer pairs with an amplicon length of about 560 bp, 179 length of 250 bp while the NEB VSS panel has 74 primer pairs with an amplicon length of about 560 bp,
180 bp on average. 180 on average.
181 **QIAseq DIRECT SARS-CoV-2 enrichment panel**

181 QIAseq DIRECT SARS-CoV-2 enrichment panel

- \overline{a} 182 cDNA amplification was performed using QIAseq DIRECT SARS-CoV-2 enrichment panel
183 following manufacturer's protocols. After the emergence of variant BA.5, (June 13th, 2022), the
-
- 184 manufacturer distributed an auxiliary primer set as a spike-in to the existing protocol. The samples from
- 185 May 17th and onward were amplified using the spike-in to the enrichment panel. The detailed protocol 185 May 17th and onward were amplified using the spike-in to the enrichment panel. The detailed protocol
186 is publicly available at <mark>dx.doi.org/10.17504/protocols.io.rm7vzy39rlx1/v4</mark>
- 186 is publicly available at dx.doi.org/10.17504/protocols.io.rm7vzy39rlx1/v4

187 NEB VSS SARS-CoV-2 enrichment panel

- cDNA amplification was performed utilizing the NEB VSS SARS-CoV-2 enrichment panel following
189 manufacturer's protocol. Due to the emergence of BA.2.12, there was a change in the primer version
-
- 190 from VSS v1a to VSS v2a starting from the week of March 1st. There was also a spike-in introduced in
- 191 the primer pairs as an update to the kit due to the emergence of BA.5. The samples from the week of
- 192 the primer pairs as an update to the to the kit due to the kit due to the kit due to the kit due to the ki
192 the kit due to the annul samples from the week of Ba.5. The detailed protocol 192 May 11" and onward were amplified using the enrichment panel with spike-in. The detailed protocol is
193 publicly available at <mark>dx.doi.org/10.17504/protocols.io.3byl4bwervo5/v2</mark>

publicly available at dx.doi.org/10.17504/protocols.io.3byl4bwervo5/v2
194 High throughput Sequencing

194 High throughput Sequencing

- 195 QIAseq DIRECT amplicons were sequenced using Illumina MiSeq (Illumina, San Diego, CA). NEB
-
- 197 Technologies, Oxford, UK). Every sample (n = 182) was amplified using both QIAseq DIRECT SARS-CoV-2
- 198 enrichment panel and NEB VSS SARS-CoV-2 panel (n=364). The libraries of NEB VSS amplicons were
- 199 enrepared using ligation sequencing kit (Oxford Nanopore Technologies Ligation Sequencing Kit (SQK-
- 200 LSK109), Cambridge, UK) as described in the publicly available protocol
- ر
201 **dx.doi.org/10.17504/protocols.io.3byl4bwervo5/v2** run on a R.9.4 flo[.] 201 dx.doi.org/10.17504/protocols.io.3byl4bwervo3/v2 run on a R.9.4 flow cell (R9.4.1) for 720h.
- 202 Data analysis, quality metrics and variant calling

218 C-WAP takes into account the number of raw reads that align to the reference sequence and
219 pass filter, *i.e.*, read lengths after adaptor trimming \geq 30 and minimum read quality \geq 20 within a sliding 220 window of width 4 bases. C-WAP outputs a comprehensive report along with several distinct quality 221 metrics (Table 1). These include the percent of reads aligned to SARS-CoV-2 genome, coverage depth of 222 the sequencing reads at every genomic coordinate of the SARS-CoV-2 genome, read quality, coverage 223 depth over the entire breadth of the SARS-CoV-2 genome, absolute counts of genomic coordinates with 224 less than 10X coverage or no coverage, scaled counts of genomic coordinates that with less than 10X 225 coverage or no coverage, and variant abundance estimation using Freyja, kallisto, and Kraken. 225 coverage or no coverage, and variant abundance estimation using Freyja, kallisto, and Kraken.

248 NEB VSS and QIAseq DIRECT and sequenced in ONT and Illumina MiSeq respectively) were chosen based 248 NEB VSS and QIAseq DIRECT and sequenced in ONT and Illumina MiSeq respectively) were chosen based

291 Comprehensive QC metric analysis

301 Coverage depth vs coverage breadth:
302 We compared sequencing depth versus breadth of the SC2 genome for both amplicon kits, 303 QIAseq DIRECT and NEB VSS. The ideal sequencing run would have the maximum sequencing depth 304 (greatest number of reads aligned) over the entire breadth (100%) of the genome, indicating even 305 coverage over all genomic coordinates. Across the time course of this study, the coverage depth versus 306 breadth for each amplicon kit used for each month of wastewater surveillance (Fig 4) improved as we 307 optimized our sample collection and sequencing methods, with values for the metric converged towards 308 the ideal in June compared to January. Comparison of the amplicon panels shows that the NEB VSS 309 panel has lower genome coverage when compared to the QIAseq DIRECT panel for January and 310 February, but by June the breadth versus depth for all sequencing runs are similar between amplicon 311 February, but by June the breadth versus depth for all sequencing runs are similar between amplications are similar between amplications are similar between amplications are similar between amplications are similar 312 C

312 Genome coverage across ORF1ab, S, M, and N genes of SC2 genome:
313 Calculations of absolute and scaled coverage for each nucleotide site within all SC2 genes (5' 314 UTR, ORF1ab, S, ORF3a, E, M, ORF6, ORF7ab, ORF8, N, ORF10, 3'UTR) was extracted from the C-WAP 314 UTR, ORF1ab, S, ORF6, ORF7ab, ORF8, ORF8, ORF8, ORF9, ORF9, ORF9, ORF9, N, ORF9, N, ORF9, N, ORF9, ORF9, O

 \overline{r} 315 report. Genome coverage for four key genes, namely ORF1ab, S, M and N genes, was used to detect
316 characteristic mutations of the variants from January through June 2022 (Fig 5) during this study. Both 317 NEB VSS and QIAseq DIRECT enrichment panels had more under-covered (<10x) sites within the S gene 318 when compared to coverage of the remaining three key genes. 255 samples enriched by QIAseq DIRECT 319 showed under-coverage in the S gene, versus an average of 166 samples for the other three key genes, 320 while 109 samples enriched by NEB VSS showed S gene under-coverage, versus an average 92.3 321 samples? for the other three genes. An overall poor performance of QIAseq DIRECT on the M gene was 322 observed across all months of sampling, when compared to NEB VSS, with the average scaled M gene 323 under-coverage across all QIAseg DIRECT samples 117% greater than that of NEB. In contrast, the NEB 324 VSS amplicon panel was observed to have more under-covered sites on ORF1ab and N genes across all 325 months of sampling-78% and 13% greater average scaled under-coverage, respectively.

335 monother contribution average scaled understanding \sim 326 Concordant Correlation Coefficient

327 To further assess performance and agreement between the two amplicon panels and the
328 variant callers used in this study, we computed concordant correlation coefficients (CCC) to compare the 329 performance of the top two variant callers (9), Freyja and kallisto, using a subset of high-quality 330 sequenced samples, determined by having good QC metrics with uniform coverage across the genome 331 (Fig 6). The CCC was positive for each kit, though under 0.25 for each, indicating mild agreement 332 between the variant callers (Fig 6). The CCC between the variant callers was relatively higher for QIAseq 333 DIRECT samples (0.2113 as opposed to 0.0102 for NEB VSS) and had a 95% confidence interval that did 334 not span 0, indicating a statistically significant agreement. In contrast, the CCC for NEB VSS samples had 335 a 95% confidence interval spanning 0, indicating there is likely no relationship between the variant 336 detection calls by Freyja and kallisto. Accordingly, this suggests that for NEB VSS samples with GridION 337 sequencing, one variant caller may be a better choice than the other to produce the most accurate $\mathbf{337}$ sequencing, one variant caller may be a better choice than the other to produce the most accurate

 \overline{r} 338 results, while for QIAseq DIRECT samples with MiSeq sequencing, the choice of variant caller may be less

339 important.
340 Circulating variant estimation: 340 Circulating variant estimation:

341 During the sampling period, our surveillance system not only captured the major and minor
342 variants circulating within the community but also detected the emergence of new variants. We 343 combined the variant results from all 364 sequences from 182 samples, agnostic to the kit and 344 sequencing platform used, to observe the general trend of circulating variants using Freyja as its 345 database is updated more frequently. The MD wastewater samples clearly identified the emerging 346 variants of concern like BA.1, BA.2.12, BA.4.6 and BA.5 from January 2022 through June 2022 (Fig 7, 347 Supplementary Fig 1). Omicron BA.1 was the dominant circulating variant when the wastewater 348 sampling began in January 2022. January 29th samples showed signs of emergence of BA.2, and 349 dominant detection of BA.2 was observed from March 30th, 2022. BA.2.12 was detected starting from 350 end of March 2022, followed by BA.4 and BA.5 in mid-May, and dominantly detected starting end of 351 May 2022. We also observed traces of BA.4.6 in mid to late June, agreeing with the onset of BA.4.6 in and the control of A.4.6 in Maryland.
352 in middle traces of Barana in Maryland with the onset of BA.4.6 in the onset of BA.4.6 in the onset of BA.
4.6 in middle traces of BA.4.6 in Maryland with the onset of BA.4.6 in th 352 clinical cases in Maryland.
353 **Early detection of BA.2:**

354 The BA.2 lineage was first detected in samples collected on January 29th, 2022, and again on 355 January 31, 2022 with both the NEB VSS and QIAseg DIRECT enrichment panels. The first clinical 356 reporting of the BA.2 lineage in the entire state of MD by the CDC was on January 27th, 2022 (variant 357 data is not available per zip code). To verify the early detection of BA.2 in these wastewater samples, 358 every mutation identified using both enrichment panels was examined for six days (January 27th-359 February 1st) surrounding the first purported appearance of BA.2 (Fig 8A). Detected mutations for each 360 day were categorized based on their presence/absence in BA.1 and BA.2 lineage sequences. Mutations 360 day were categorized based on their presence/absence in BA.1 and BA.2 lineage sequences. Mutations

371 and clinical samples. BA.2 diagnostic mutations were detected with frequencies up to at least 0.5 in

372 some samples, while most detected BA.1-incompatible mutations were present with frequency of 0.25 and samples, which most detected BA.1-incompatible most detected BA.1-incompatible mutations were present with
1983 Some samples, which first with frequency of 0.255 Some present with frequency of 0.255 Some present with

373 or greater. In contrast, the mutations detected on January 28 include no BA.2 diagnostic mutations and
375 BA.1-incompatible mutations are largely present in low frequency. This shows the presence and 376 frequency of BA.2 diagnostic mutations and the overall profile of mutations observed at the early 377 frequency of BA.2 angles mutations and the overall profile of mutations observed at the early
377 flatection dates, January 29th and 31st, mimic that from a later sample, from March 30th, when BA. 377 — detection dates, January 29''' and 31'', mimic that from a later sample, from March 30''', when BA.2 was
378 — known to be present in the WWTP service area.

378 known to be present in the WWTP service area.
379 **Realtime submission of surveillance data**:

380 After the sequencing protocol was optimized and QC metrics were in place, we made an effort 381 to quantify the minimum time from sample collection to sequence analysis and release. Composite 382 grabs for the week of June 28th, 2022, were collected at 6 am from the treatment plant and the time to 383 process these samples was recorded. Total nucleic acid extraction, cDNA synthesis, amplification using $\frac{1}{3}$ process these samples was recorded. Total nucleic acid extraction, compliment, amplification using using $\frac{1}{3}$

 \mathbf{r} 384 NEB VSS enrichment panel, and loading of the libraries on to Oxford Nanopore GridION took 30hrs. After
385 16hrs, we had collected sufficient sequence data that passed QC to detect all the characteristic and 386 diagnostic mutations for BA.5. Data analysis using C-WAP, upload of this data to NCBI, and display on the 387 dashboard took 11 hrs. The total turnaround time from sample collection to dashboard display was 388 dashboard took 11 hrs. The total turnaround time from sample collection to database any proposed
388 dashboard display was also to dashboard display was also to dashboard display was also to database and the $\frac{388}{286}$

389 Discussion Six months of wastewater surveillance, made possible through the partnership with a
391 vastewater treatment plant in Maryland, detected new variants as they emerged along with major and 392 minor variants circulating in the community. From a clinical perspective, this level of resolution of 393 community disease dynamics could underpin traditionally monitored clinical testing and help public 394 health officials to serve communities more efficiently. A wastewater surveillance system fills data gaps 395 for areas where clinical testing and surveillance may be limited, including underserved communities 396 with limited access to testing sites.

396 with limited access to testing sites. 397 The laboratory and bioinformatic methods employed in this study confidently detected multiple
398 circulating SARS-CoV-2 (SC2) variants in wastewater samples using amplicon-based targeted enrichment 399 panels. Several enrichment panel kits were evaluated, but only two, the QIAseq DIRECT and NEB VSS 400 panels were pursued as the best options for wastewater samples.

401 **band The viral load in wastewater, when compared to the clinical cases, indicated a low rate of clinical** 402 testing as the pandemic began to wane (Fig 2). In other words, there were higher levels of SC2 in the 403 community, based on wastewater analysis, than were being estimated based on reports from clinical 404 testing. This is perhaps because at-home test kits became widely available within the community around 405 the same time as this study commenced. From wastewater data, it is evident that clinical testing did not 406 fully capture the wave of infections during early April to June 2022 (Fig 2). A limit of detection with

 $\frac{40}{\sqrt{2}}$ fully capture the wave of infections during early April to June 2022 (Fig 2). A limit of detection with

{ genome copies/L to the SC2 hits was not established and so all samples were sequenced regardless of
408 RT-qPCR result (22). Having strict QC measure in place helped us to overcome this lack of a robust RT-409 gPCR LOD threshold and eliminate some poorly performing samples attributed to the lower genome 4109 qPCR LOD threshold and eliminate some poorly performing samples attributed to the lower genome
410 copies/L.

 $\frac{1}{100}$ 411 A main goal of wastewater surveillance is to track emerging and circulating variants at a
412 Community level and hopefully provide an early warning signal of emerging and increasing infections 413 without the need for community clinical information. For example, we detected BA.2 ahead of the 414 clinical findings for the state. It is important to note that the variant calls are published only at the state 415 level by CDC, not at the ZIP code level. Here we detected BA.2 at the community level covering two ZIP 416 codes 14 days ahead of BA.2 variant calls published by CDC at the state level for Maryland. This 417 emphasizes an ability of community level surveillance using wastewater: enabling a more focused public

418 health local response during a pandemic.

419 **health local response in SC2** variants, mutations across the S-gene play a crucial role in variant calling. Research is 420 ongoing to elucidate the mechanisms involved but the mutations may boost infectivity and 421 transmissibility through increased spike density, enhanced cleavage and host cell uptake, and increased 422 viral load and ability to evade host immune responses (23). Mutations may also interfere with laboratory 423 testing and complicate epidemiological monitoring by interfering with detection in sequence-based 424 tests. If a mutation occurs in the part of the viral genome assessed by a PCR test, the sample may result 425 in gene "dropout." We observed a significant drop in coverage of the S gene with the NEB VSS panel on 426 the week of May 11. For this same week, RT-qPCR of these samples had 90,587 genome copies/L 427 indicating a high SC2 viral load in the community (the range of genome copies for the duration of this 428 study was from 350 genome copies/L to 99840 genome copies/L). The significant drop in S gene 429 coverage raised concerns and the vendor was contacted and spike-in to the primer pool 1 was obtained 430 to overcome the dropout due to the rise of BA.5 sub variants. When we repeated the amplification and

 \overline{a}

 $\ddot{}$ 431 sequencing of samples from the week of May 11 using the primer spike-in (NEB VSS), we observed
432 improved coverage on the S gene because of the three characteristic mutations (S:S371F, S:T376A, 433 S:D405N) detected with the spike-in that were not detected with the original primer panel. 434 A:D405 A 435 with QIAseq DIRECT enrichment panel. This same mutation was not detected until the week of June 1 436 using NEB VSS enrichment panel. A spike-in for the QIAseq DIRECT enrichment panel was introduced 437 from the week of June 13. The spike-in primers in the QIAseq DIRECT panel had a slightly higher 438 concentration of primers compared to its original panel across this region (23082-23144 bp). While 439 there was not a full dropout in this region (23082-23144 bp), the observed coverage was lower, and the 440 concentration of the primers (QIAseq_170_RIGHT, QIAseq_172_LEFT, and QIAseq170-2_RIGHT) were 441 increased to provide more uniform coverage within that gene. Since mutations may affect detection, 442 treatment, and prevention, it is important to identify strains correctly to direct public health 443 containment strategies (5). To address this type of limitation, there are studies that incorporate targeted 444 sequencing of only variable regions of interest in the genome, particularly those regions that contain 445 mutations unique to specific variants of concern (5). In addition, there are studies that apply PCR 446 amplifying, cloning, and sequencing a 1.5[®]kb region of the spike protein gene to confirm the linkage of 447 mutations of interest to understand all the circulating variants in a complex sample (24). While these 448 approaches provide valuable information on a very targeted genomic area where mutations are known 449 to occur, mutations at other genomic coordinates, which might be indicative of emergent variants and \sim 450 to occur , mutations at our coordinates, which might be indicated variants, will not be obtained. 450 variants, will not be obtained.

In practice, when a diagnostic or surveillance test is based on targeted amplification, for it to be
452 able to detect variations in the genome of pathogens, it is necessary to regularly update the primer pairs 453 and/or alter the target regions used in the detection systems or use several target genes of the 454 infectious agent in the same test reaction to minimize the risk of false negative results (5). Both

 $\frac{4}{\sqrt{3}}$ infectious agent in the same test reaction to minimize the risk of false negative results (5). Both $\frac{1}{\sqrt{3}}$

 ϵ enrichment panels evaluated in this study consistently updated the primer pairs for the detection of
456 – circulating variants. In an ARTIC primer approach where entire primer versions are updated, the 457 emergence of new variants renders any remaining primers obsolete (25, 26). This stands in contrast to 458 the spike-in approach, where the spike-in is introduced to the original pools, minimizing the 459 regeneration of old primers and revitalizing their performance. Many enrichment panels contain 460 degenerate primer designs of polymorphic regions of the genome to allow more robust amplification of 461 variable strains. Also, strategically designed primer pairs for consistent coverage are essential for highly 462 evolving genomes like SC2 (5). Keeping the challenges of uniform coverage within the targeted site, 463 primer binding efficiency, and adaptation to several sequencing approaches in mind, choosing a suitable 464 target enrichment panel and pairing it with the suitable library preparation kit based on the sequencing 465 platform may play a critical role in identifying the circulating and emerging variants.

466 black may be a critical genome coverage metrics for four key genes (ORF1ab, S, M and N genes), 467 both QIAseg DIRECT enrichment panel and NEB VSS enrichment panel had substantial under-covered 468 both Caseq on the Sugene when compared to the other three genes. In the NEB VSS SARS-CoV-2 enrichment 469 panel, there are 10 primer pairs targeting the S gene (genome coordinates: 21563-25384) with an 470 overlapping primer pair included to enable detection of BA.5 specific mutations. The S gene is the most 471 mutation-prone region of SC2 genome, which means that primer binding sites for this gene can play a 472 major role in variant calling performance on a mixed sample like wastewater. For the M gene, the 473 QIAseq DIRECT enrichment panel had lower coverage across all months when compared to NEB VSS 474 enrichment panel (Fig 5). Two characteristic mutations within the M gene used to assess all Omicron sub 475 variants correspond to primer binding regions in the QIAseq DIRECT enrichment panel, while neither 476 mutation is in a primer binding region for NEB VSS. The QIAseq DIRECT enrichment panel has more 477 amplicons with more primer pairs (222 primer pairs total, whereas NEB VSS panel has 74 primer pairs) 478 and is more suitable for short read sequencing (~250bp amplicon length) which results in high coverage 478.8 and is more suitable for short read sequencing (250

 \overline{a} $\ddot{\epsilon}$ 479 across the genome. But there is a greater chance of mutations occurring in a primer binding site,
480 especially for rapidly evolving genes, such as the S gene. The NEB VSS primer panel somewhat mitigates 481 this with longer amplicon length (~560bp) and fewer primer pairs. Continuous evaluation of current and 482 emerging target enrichment panels is essential to accurately detect existing and evolving SC2 variants examples target enrichment panels is essential to accurately detect existing and evolving SC2 variants.
483 from wastewater.

 $\frac{1}{2}$ 484 During the development of C-WAP, a critical performance assessment of various variant callers
485 on *in silico reads of mixed variants revealed that Freyja was the most suitable variant caller on short* 486 read data and kallisto was the most suitable variant caller for the long read data (9). The concordant 487 coefficient analysis on our real-world data agreed with those previous findings (Fig 6) However, to 488 solidify these conclusions, further investigations are warranted, particularly with a larger sample size. 489 Additionally, considering the evolving nature of viruses, future studies should explore the impact of 490 different amplification kits on variant calling accuracy.

491 We tested the feasibility of the real time submission of data to support the public health 492 response. Real time submission and publication to the dashboard within 57 hours was possible because 493 of real-time long read sequencing through Oxford Nanopore GridION. After just 16 hrs of sequencing, 494 there was enough accumulated sequencing depth data that passed QC to provide high confidence in the 495 accuracy of variant calling. Even though the run time in GridION was chosen to be 72hrs, most of the 496 data were collected in the initial 20hrs after sequencing started. However, to ensure high quality data, 497 we multiplexed only 9 samples per flow cell on GridION, compared to 28-32 possible samples on 498 Illumina MiSeq. The Illumina MiSeq, despite its inherent speed limitations, presents promising prospects 499 If or near-real-time applications when Read1 data is being used. While just the Read1 data can 500 successfully pass all quality control (QC) metrics, there is a subsequent delay of up to 24 hours for 501 uploading the sequence data from a paired-end run, which might be advantageous for maximizing 502 quality scores. It is important to understand the complexity associated with multiplexing samples per

 502 quality scores. It is important to understand the complexity associated with multiplexity associate

 \mathbf{f} 503 flow cell, a factor that may necessitate adjustments based on the viral load. Our team has established
504 best practices for the efficient collection, organization and surveillance of sequence data (21). Analyzing 505 the turnaround time from sample collection to NCBI data release revealed a median duration of 506 approximately 28 days for the samples in this study. However, this exercise has illuminated the potential 507 for real-time data submission, enabling immediate surveillance insights. Regardless of the sequencing 508 technology, near real time data submission is possible through wastewater surveillance which will 509 support community level decision making easier during pandemic. Incorporation of automated liquid 510 handling robots could further reduce time from sample receipt to data publication.

511 bandler bandling Due to the dynamic and swiftly evolving nature of SARS-CoV-2, our dedication to real-time 512 dashboard updates and the dissemination of optimized protocols to the wastewater surveillance 513 community, this study has some limitations. One limitation was the inability to delve into the genuine 514 distinctions in raw wastewater and composites beyond a one-week sample analysis period where we 515 explored both raw wastewater grabs (February 23rd to February 28th) and composite grabs (February 516 23rd to February 28th). We needed to investigate the feasibility of weekly sample pooling as a strategy 517 (February 28th, 2022, and onwards) to reduce the processing workload in our laboratory, and when we 518 did not find any differences in the viral load and other QC metrics when the sequences, regardless of 519 enrichment panel, were analyzed from that week, we proceeded with weekly sample pooling. 520 Additionally, we were constrained in exploring the potential benefits of multiplexing varying sample 521 guantities on GridION flow cells to comprehend sequencing depth. This study is also limited by not 522 including an evaluation of other commercially available enrichment panels, such as ARTIC V4 or Resende 523 (26, 27). Moreover, the study was hindered in its capacity to investigate spike-in studies with known 524 concentration of the virus in various matrices, which are essential for establishing a true limit of 525 detection of the virus in various matrices, which are establishing a true limit of establishing a true limit of \sim

es.
546 **- Peferen**

546 References 547 1. Karthikeyan S, Levy Jl, De Hoff P, Humphrey G, Birmingham A, Jepsen K, et al. Wastewater
548 Sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature. 2022;609(7925):101-8. $\frac{4}{3}$ second reveals early cryptic SARS-CoV-2 variant transmission. Nature. Nature. 2022;609(7925):101-8.

 \overline{a} $\frac{1}{2}$ 549 2. Ahmed W, Bertsch PM, Bibby K, Haramoto E, Hewitt J, Huygens F, et al. Decay of SARS-CoV-2
550 and surrogate murine hepatitis virus RNA in untreated wastewater to inform application in wastewater-
551 based epidemiol 552 3. Achak M, Alaoui Bakri S, Chhiti Y, M'Hamdi Alaoui FE, Barka N, Boumya W. SARS-CoV-2 in 552 3. Achak M, Alaoui Bakri S, Chhiti Y, M'Hamdi Alaoui FE, Barka N, Boumya W. SARS-CoV-2 in
553 hospital wastewater during outbreak of COVID-19: A review on detection, survival and disinfection
554 technologies. Sci Tota 553 hospital wastewater during outbreak of COVID-19: A review on detection, survival and disinfection
554 technologies. Sci Total Environ. 2021;761:143192.
555 4. Fontenele RS, Kraberger S, Hadfield J, Driver EM, Bowes D, 555 technologies. Science Environment Products (SSS)
555 the Southenele RS, Kraberger S, Hadfield J, Drivi
556 sequencing of SARS-CoV-2 in wastewater provides 556 5. Forteneled RS, Analysis J, Analysis J, Hadriel J, Driver Em, Bowes D, Holland La, Et al. High-through
556 557 2021;205:117710. 556 sequencing of SARS-CoV-2 in wastewater provides insights into circulating variants. Water Res.
557 2021;205:117710.
558 5. Smyth DS, Trujillo M, Gregory DA, Cheung K, Gao A, Graham M, et al. Tracking cryptic SARS-C 559 2 lineages detected in NYC wastewater. Nat Commun. 2022;13(1):635. 560 6. Farkas K, Hillary LS, Malham SK, McDonald JE, Jones DL. Wastewater and public health: the 559 2 lineages detected in NYC wastewater. Nat Commun. 2022;13(1):635. 561 Farkas K, Hillary Louis K, Hillary Louis Communic Health Department Indiana Public Health. 2020;1
562 The 20.
562 The D. Wastewater surveillance for monitoring COVID-19. Curr Opin Environ Sci Health. 2020;1 561 potential of wastewater surveillance for monitoring COVID-19. Curr Opin Environ Sci Health. 1
1952 - 20.
1920;17:10:20:14:14-2020;17:14-4-2020;17:14-4-2020;17:14-4-2020;17:14-01-2020;17:14-5:14-4-5:14-4-5 563 <mark>7</mark>.
564 Wa 563 7. Aguiar-Oliveira ML, Campos A, A RM, Rigotto C, Sotero-Martins A, Teixeira PFP, et al. 564 Wastewater-Based Epidemiology (WBE) and Viral Detection in Polluted Surface Water: A Valuable To
565 for COVID-19 Surveillance-A Brief Review. Int J Environ Res Public Health. 2020;17(24).
566 8. Flamouda M, Mustafa F, 567 CoV-2: Lessons learnt from recent studies to define future applications. Sci Total Environ. 568 2021;759:143493. 569 9. Kayikcioglu T, Amirzadegan J, Rand H, Tesfaldet B, Timme RE, Pettengill JB. Performance of ---- -----,------------
569 9. Kayikcioglu
570 methods for SARS-569 Forman H, Amiran J, Amiran Languer, Amiran J, Termina L, Thuman H, Testanguer Pressumment of the
570 Feerl, 2023;11:e14596.
571 Peerl, 2023;11:e14596. 570 methods for SARS-CoV-2 variant detection and abundance estimation within mixed population samples.
571 PeerJ. 2023;11:e14596.
572 10. Wang Y, Hu X, Yang L, Chen C, Cheng H, Hu H, et al. Application of High-Throughput S 571 PeerJ. 2023;11:e14596. 573 Technology in the Pathogen Identification of Diverse Infectious Diseases in Nephrology Departments.
574 Diagnostics (Basel). 2022;12(9). 573 Technology in the Pathogen Identification of Diverse Infectious Diseases in Nephrology Departments.
574 Diagnostics (Basel). 2022;12(9).
575 11. Suminda GGD, Bhandari S, Won Y, Goutam U, Kanth P $575 \qquad 11 \qquad \qquad$ Suminda GGD, Bhandari
576 sequencing technologies in the d 576 sequencing technologies in the detection of livestock pathogens, diagnosis, and zoonotic surveillance.
577 Comput Struct Biotechnol J. 2022;20:5378-92. 577 sequencing technologies in the detection of livestock pathogens, anglesse, and examples can change to
577 Semput Struct Biotechnol J. 2022;20:5378-92.
578 Semput Stock pathogens, and an analysis of livestock pathogens 577 Comput Struct Biotechnol J. 2022;20:5378-92. 578 12. Ko KKK, Chng KR, Nagarajan N. Metagenomics-enabled microbial surveillance. Nat Micro
579 2022;7(4):486-96.
580 13. Iwu-Jaja C, Ndlovu NL, Rachida S, Yousif M, Taukobong S, Macheke M, et al. The role of 581 wastewater-based epidemiology for SARS-CoV-2 in developing countries: Cumulative evidence from 581 wastewater-based epidemiology for SARS-CoV-2 in developing countries: Cumulative evidence f
582 South Africa supports sentinel site surveillance to guide public health decision-making. Sci Total 582 was teached epidemiology for SARS-CoV-2 in developing commerce community constructions.
582 South Africa supports sentinel site surveillance to guide public health decision-making. Sci Total Envir
583 2023;903:165817. 582 South Africa supports sentinel site surveillance to guide public health decision-making. Sci Tot
583 2023;903:165817.
584 14. GenomeTrakr-protocols-wastewater [Available from: https://www.protocols.io/file-585 manager/682C9E830C0A11EC806D0A58A9FEAC02. 586 15. GenomeTrakr-protocols-stewate from: https://www.protocols-genome.com/
587 of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. Biol Me 586 15. Freed NE, Vlkova M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome sequench 587 of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. Biol Methods
588 Protoc. 2020;5(1):bpaa01 589 16. Swift BioSciences. "NEW-Swift Normalase™ Amplicon SARS-CoV-2 Panels." [Available from: 590 https://swiftbiosci.com/swift-normalase-amplicon-sars-cov-2-panels-3/ 590 11ttps://swiftbiosci.com/swift-normalase-amplicon-sars-cov-2-panels-3/
591 17. VarSkip Multiplex PCR Designs for SARS-CoV-2 Sequencing. 2021. Reprint, New England Biola 591 **https://wift-normalase-amplication-syift-normalism**
592 https://swift-normalase-amplicon-sars-cov-2-Sequencing-2021
592 https://github.com/nebiolabs/VarSkip. 591 17. VarSkip Multiplex PCR Designs for SARS-CoV-2 Sequencing. 2021. Reprint, New England Biolabs
592 Inc., 2021 [Available from: <u>https://github.com/nebiolabs/VarSkip</u>.
593 18. The Pango nomenclature is being used by re 593 Inc., 2021 The Promote from the Engineer Community Community Community 1986
593 IS. The Pango nomenclature is being used by researchers and
594 track the transmission and spread of SARS-CoV-2, including variant. 594 track the transmission and spread of SARS-CoV-2, including variants of concern. [Available from:
595 https://cov-lineages.org/ 595 https://cov-lineages.org/
- including variants of SARS-Covernand of Covernand variants of concernsive from: [Available from: [Available f

 $\frac{1}{2}$ https://cov-lineages.org/.

 $\ddot{}$ 596 19. Cui Y, Peng L, Hu Y, Lai HJ. Assessing the Reproducibility of Microbiome Measurements Based on
597 Concordance Correlation Coefficients. J R Stat Soc Ser C Appl Stat. 2021;70(4):1027-48.
598 20. Palarea-Albaladejo 599 censored data under a compositional approach. Chemometrics and Intelligent Laboratory Systems.
600 2015;143:85-96. 2015;143:85-96. 601 21. Timme RE, Woods J, Jones JL, Calci KR, Rodriguez R, Barnes C, et al. SARS-CoV-2 wastewater
602 variant surveillance: pandemic response leveraging FDA's GenomeTrakr network. medRxiv. erection
601 21. Timme R
602 variant surveillan Frame Re, Woods J, Jones J, Jones J, Jones J, Jones J, James J, Jones J, J. J
602 The Variant surveillance: pandemic response leveraging FDA's GenomeTrakr network. medRxiv.
603 The 2024:202 603 variant 2024:2024.01.10.24301101.
604 variant Surveillance: pandemic response leveraging Fandes oc. et al. Variability in RT-gPCR assay 604 22. Bivins A, Kaya D, Bibl
605 parameters indicates unrelia 605 parameters indicates unreliable SARS-CoV-2 RNA quantification for wastewater surveillance. Water Re
606 2021;203:117516. 605 parameters indicates unreliable SARS-CoV-2 RNA quantification for wastewater surveillance. Water Res.
606 2021;203:117516.
607 23. Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S, et al. Emerging SARS-606 2021;203:117516. 607 23. Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S, et al. Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines (Basel). 2021;9(10).
609 24. Jwamoto R, Yamaguchi K, Katayama K, Ando H, Setsukinai KI, Kobayashi H, et al. Identification of
610 SARS-Co SARS-CoV-2 variants in wastewater using targeted amplicon sequencing during a low COVID-19 612 25. ARTIC primer revamping [Available from: https://community.artic.network/c/laboratory/6 613 26. Tyson JR, James P, Stoddart D, Sparks N, Wickenhagen A, Hall G, et al. Improvements to the 613 26. Article finder revails from the from: https://community.org/munity.org/2013 26. Tyson JR, James P, Stoddart D, Sparks N, Wickenhagen A, Hall G, et al. Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 g 614 ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. bioRxiv. 2020.
615 27. Paola Cristina Resende FCM, Sunando Roy, Luciana Appolinario, Allison Fabri, Joilson Xavie 614 ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. bioRxiv. 2020. 616 Kathryn Harris, Aline Rocha Matos, Braulia Caetano, Maria Orgeswalska, Milene Miranda, Cristiana
617 Garcia, André Abreu, Rachel Williams, Judith Breuer, Marilda M Siqueira. SARS-CoV-2 Genomes 617 Garcia, André Abreu, Rachel Williams, Judith Breuer, Marilda M Siqueira. SARS-CoV-2 Genomes
618 Recovered by Long Amplicon Tiling Multiplex Approach Using Nanopore Sequencing and Applicable to 618 Full Recovered by Long Amplicon Tiling Multiplex Approach Using Nanopore Sequencing and Applical
619 Fother Sequencing Platform. BioRXIV. 2020. 618 Recovered by Long Amplicon Tiling Multiple
619 Other Sequencing Platform. BioRXIV. 2020.
620 620

- 621 Acknowledgements
622 Ve gratefully acknowledge the wastewater treatment plant for collecting samples for this study and
- 623 sharing it with us. We acknowledge Dr. Leena Malayil and Dr. Amy Sapkota, School of Public Health,
- 624 University of Maryland for introducing us to the WWTP for sample collection. We acknowledge
- 625 Covid Trakr working groups at the Center for Food Safety and Applied Nutrition (CFSAN) for discussion
- 626 that facilitated this manuscript. We also acknowledge the support of CFSAN high performance
- 627 computing engineers G. Engelbach, J. Payne, K. Konganti, and M. Hammond. We acknowledge all data
- 628 contributors for generating the genetic sequence and metadata and sharing via the GISAID Initiative, on
- 629 contributors for generations for general sequence and metals equence and metabology via the GISA 629 which this research is partly based.

$\overline{1}$

639 Funding

- 640 This project was supported in part by funding from the American Rescue Plan Act of 2021. Jasmine
641 Amirzadegan, Candace Hope Bias, Kathryn Judy, and Tammy Walsky's participation was supported by an
-
- 642 appointment to the Research Participation Program at the U.S. Food and Drug Administration
- 643 administered by the Oak Ridge Institute for Science and Education through an interagency agreement
- 644 between the U.S. Department of Energy and the U.S. Food and Drug Administration. Tunc Kayikcioglu
- 645 and Dietrich EppSchmidt received financial support from Joint Institute for Food Safety and Applied
- 646 Nutrition (JIFSAN), University of Maryland as part of financial assistance award U01FD001418 funded by
- 647 the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS).
- 648 The funders had no role in study design, data collection and analysis, decision to publish, or preparation \sim 500 The funders had no role in study design, data collection and analysis, decision to publish, or preparation \sim
-

649 of the manuscript. 650
651

651 Table 1: QC metrics monitored for data submission and further analysis.
652 Schematic Fig1 : Weekly collection and processing of composite samples: From February 23rd through

653 June 30, 2022, daily composite samples were pooled into a single sample of two biological replicates per 653 June 30, 2022, daily composite samples were pooled into a single sample of two biological replicates per

 $\overline{}$ 654 week. Each biological replicate was then split into three 40mL technical replicates, resulting in six
655 samples per week that was taken into further processing.

656 Figure 1: Flowchart of was tewater processing and analysis workflow: Was tewater samples collected

657 from the treatment plant were pooled by week and the total nucleic acid (TNA) was extracted using

658 From ega Enviro TNA kit. Genomic DNA was digested with ezDNase prior to cDNA synthesis using

659 Superscript IV Reverse Transcriptase. The cDNA was amplified using either NEBNext VarSkip Short (VSS)

660 primers for long-read (~550bp) sequencing on the Oxford Nanopore Technologies GridION or QIAseq

661 DIRECT (QIAseq) primers for short-read (~250bp) sequencing on the Illumina MiSeq. All sequences were

662 processed through the CFSAN Wastewater Analysis Pipeline, producing a report that included QC

663 metrics as well as relative abundance of variants. Sequences that pass QC are submitted to NCBI and the

664 variant calls were published in the FDA dashboard.

665 Figure 2: SARS-CoV-2 viral load and relationship to clinical cases: The relationship of wastewater-based

666 surveillance burden estimations and actual clinical reporting, with clinical data plotted against the viral

667 genome copies/L, over time. The rolling 7-day average of new clinical SARS-CoV-2 cases (black) in the

668 sewer shed graphed alongside the viral load over time (blue), calculated from RT-qPCR on raw

669 wastewater and 24h composite samples taken from the wastewater treatment plant. Number of cases is

670 indicated on the right-hand axis, while genome copies/L is marked on the left.

671 Figure 3: Percentage of aligned reads vs. wastewater viral load : Weekly average percent reads aligned

672 to the SC2 genome (black) and the weekly average SC2 viral load (gc/L) detected by RT-qPCR from

673 wastewater (orange). Sequencing runs/data from both enrichment panels (NEB VSS and QIAseq DIRECT,

674 n=364) included in the averaging to calculate the weekly percent reads aligned were quality filtered to \lt

 675 20% sites with 0x coverage and < 40% sites covered < 10x after alignment. 675 20% sites with 0x coverage and < 40% sites covered <10x after alignment.

|
| 676 Figure 4: Coverage depth vs coverage breadth: Sequencing depth versus breadth of the SARS-CoV-2
677 Frenome covered for each amplicon kit and every month of wastewater surveillance. Any point along a 678 given line indicates the percentage (breadth, y-axis) of the SARS-CoV-2 genome covered to the 679 corresponding sequence depth (x-axis) for that single sample. The green bar on the first panel of January 680 2022, shows an ideal sequencing run with maximum depth covering the entire genome. Each line 681 indicates one sequenced sample that resulted in <20% sites along the genome covered 0x and <40% 682 sites covered <10x after alignment. 683 Figure 5: Genome coverage across ORF1ab, S, M, and N genes of SC2 genome: Genome coverage by 684 amplicon kit for key genes used to detect SARS-CoV-2 variants from January through June 2022. The 685 averaged number of under-covered (fewer than 10 quality-filtered and trimmed reads aligned) for each 686 gene and amplicon kit over time is indicated in red, with worse coverage (poorer sequencing e and amplicated in red, with worse cover time is indicated in red, with worse coverage (poorer sequencing \sim 5 μ m \sim 5 μ 687 performance) in lighter colors.
688 Figure 6: Concordant Correlation Coefficient (CCC) analysis: concordant correlation coefficient analysis 689 on the variant calling performance of Freyja and kallisto on eleven samples between May and June 2022 690 sequenced with both NEB VarSkip Short and QIAseq DIRECT primers. A CCC of +1 indicates perfect 691 agreement, -1 indicates perfect disagreement, and 0 indicates no agreement. 692 Figure 7: Proportional abundance of SARS-CoV-2 variants detected over time: Proportional abundance 693 of SARS-CoV-2 variants detected over time, as identified by the Freyja variant caller on sequence data 694 from both the enrichment panels (NEB VSS and QIAseq DIRECT, n=364). Variants always detected in a 695 proportion of less than 1% were grouped together as "Others <1%". 696 Figure 8: Verification of the BA.2 variant detection in wastewater on January 29th, 2022, using both the

697 enrichment panel (NEB VSS and QIAseq DIRECT): 8A. Proportional abundance of SARS-CoV-2 variants by ر
698 day, January 27th – February 1st 2022. 8b. Frequency of BA.1 and BA.2 –characteristic mutations over

day, January 27th – February 1st 698 2022. 8b. Frequency of BA.1 and BA.2 –characteristic mutations over

- \overline{a} \mathbf{f} 699 four dates. Mutations typically incompatible with BA.1 (teal), characteristic for BA.1 or BA.2 (purple),
700 and diagnostic for BA.2 (green, in a highlighted box) are shown at their location in the SARS-CoV-2
-
- 701 genome. All depicted mutations are significant (p-value < 0.05), but smaller circles indicate lower p-
- 702 values. BA.2 was detected in the bottom three date panels.
- 703 Supplementary table1: Sample collection and pooling strategies employed in this study.
- 704 Supplementary table 2: Characteristic mutation table by C-WAP.
- 705 Supplementary table 3: Rolling 7 day average of new cases for zip codes monitored in this study along
- 706 with the wastewater viral load gc/L .
- 707 Supplementary Figure 1: SC2 population trend by sampling date using both the enrichment panel and
- 707 Supplementary Figure 1: SC2 population trend by sampling date using both the enrichment panel and
- 708 Freyja as the variant caller.
709 Supplementary reports: Example reports of the comprehensive analysis produced by C-WAP. 709 Supplementary reports: Example reports of the comprehensive analysis produced by C-WAP.

gene length \overline{b} scaled sites, poorly Average

ORF1ab

Number of poorly covered
sites, scaled

SC-2 variants Omicron: BA.1 Omicron: BA.2 Omicron: BA.2.12 Omicron: BA.3 Omicron: BA.4 Omicron: BA.4.6 Omicron: BA.5 Other B.* Other B.1.* Omicron: B.1.1.529 A Sublineages X^{*}: Recombinants Others $< 1\%$

